Termed sarcopenic obesity, it is characterised by the concurrent decline in muscle mass and function along with increased levels of adipose tissue and is associated with higher risk of disability, metabolic dysfunction, comorbidities, e.g., T2D, chronic kidney disease, cardiovascular disease, and all-cause mortality [2, 3]
Grace E, Goldblum O, Renda L, Agada N, See K, Leonardi C, Menter A
Clinical trials have shown significant weight loss, often surpassing 15% of initial body weight
Conversely, if you are eating significantly less because of the combined nausea of the medications, you should watch for signs of low blood sugar (hypoglycemia), such as shakiness or dizziness
The threat of patent litigation, particularly when compounding a drug in shortage, remains the most significant and unresolved conflict in this space